Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Human Metapneumovirus (2)
- Phase Separation (2)
- Phosphoprotein (2)
- Viral Replication (2)
- Co-infection (1)
-
- Fusion protein. (1)
- Human airway epithelium (1)
- Human metapneumovirus (1)
- Human metapneumovirus (HMPV) (1)
- Inclusion Bodies (1)
- Inclusion Body (1)
- Inclusion bodies (1)
- Membrane Fusion (1)
- Minireplicon (1)
- Nucleocapsid (1)
- Paramyxovirus (1)
- Phosphorylation (1)
- RNA-dependent RNA polymerase (RdRp) (1)
- Respiratory syncytial virus (1)
Articles 1 - 4 of 4
Full-Text Articles in Biochemistry
Characterization Of The Function And Regulation Of The Hmpv Phosphoprotein, Rachel Thompson
Characterization Of The Function And Regulation Of The Hmpv Phosphoprotein, Rachel Thompson
Theses and Dissertations--Molecular and Cellular Biochemistry
Human metapneumovirus (HMPV) is a non-segmented, negative strand RNA virus (NNSV) that frequently causes respiratory tract infections in infants, the elderly, and the immunocompromised. Despite the initial identification of HMPV in 2001, there are currently no FDA approved antivirals or vaccines available. Therefore, understanding the mechanism of HMPV replication is critical for the identification of novel therapeutic targets. A key feature in the replication cycle of HMPV and other NNSVs is the formation of membrane-less, liquid-like replication and transcription centers in the cytosol termed inclusion bodies (IBs). Recent work on NNSV IBs suggests they display characteristics of biomolecular condensates formed …
Entry And Replication Of Negative-Strand Rna Viruses, Kerri Boggs
Entry And Replication Of Negative-Strand Rna Viruses, Kerri Boggs
Theses and Dissertations--Molecular and Cellular Biochemistry
Hendra virus (HeV) and human metapneumovirus (HMPV) are negative-sense, singled-stranded RNA viruses. The paramyxovirus HeV is classified as a biosafety level 4 pathogen due to its high fatality rate and the lack of a human vaccine or antiviral treatment. HMPV is a widespread pneumovirus that causes respiratory tract infections which are particularly dangerous for young children, immunocompromised individuals, and the elderly. Like HeV, no vaccines or therapies are available to combat HMPV infections. These viruses fuse their lipid envelopes with a cell to initiate infection. Blocking cell entry is a promising approach for antiviral development, and many vaccines are designed …
Pneumovirus Infections: Understanding Rsv And Hmpv Entry, Replication, And Spread, Jonathan T. Kinder
Pneumovirus Infections: Understanding Rsv And Hmpv Entry, Replication, And Spread, Jonathan T. Kinder
Theses and Dissertations--Molecular and Cellular Biochemistry
Pneumoviruses including human metapneumovirus (HMPV) and respiratory syncytial virus (RSV) are significant causes of respiratory tract infections globally. Children, elderly, and immunocompromised patients are at the greatest risk for developing severe infections, which can have devastating outcomes. Although these viruses are ubiquitous with significant impacts on human health, there are no antivirals or vaccines available. The only FDA approved therapy is a monoclonal antibody for RSV, given prophylactically during the infectious season, and this treatment is only available for high risk infants. The work presented in this thesis aims to increase our understanding of how these viruses enter, replicate, and …
Critical Events In Human Metapneumovirus Infection: From Entry To Egress, Brent A. Hackett
Critical Events In Human Metapneumovirus Infection: From Entry To Egress, Brent A. Hackett
Theses and Dissertations--Molecular and Cellular Biochemistry
Human metapneumovirus (HMPV) is a respiratory pathogen in Paramyxovirus family that demonstrates extremely high morbidity in the population, with most individuals having been infected by the age of five. Despite the prevalence of this negative-sense RNA virus in the population for decades, it was only identified in 2001. As such, there is currently no specific treatment for HMPV and the potentially severe consequences of infection for elderly and immunocompromised individuals and particularly infants make development of antivirals targeting HMPV of high significance. HMPV constitutes a quarter of all respiratory hospitalizations among infants, placing it second only to RSV, in addition …